Influenza vaccine viral protein profiling for viral potency

Presented By:
Stephen Lock
Patrick Buckley

Speaker Biography:
Dr. Stephen Lock obtained his PhD in Physical Organic Chemistry from the University College of Swansea in 1993 and is a chartered chemist and a member of the Royal Society of Chemistry. Previously a lecturer of Chemistry at the University of Hull and a senior scientist at CCFRA he has worked for SCIEX™ in various technical roles for over 20 years. He has over 25 years’ experience in Analytical Chemistry and has presented at over 80 international meetings around the world.
Steve is currently the EMEA BioPharma Marketing and Market Development Manager of SCIEX and is also an Adjunct Professor at the University of Pannonia where he acts in a volunteer role as the Scientific Advisor for the Horváth Csaba Memorial Laboratory lead by Prof. Andras Guttman. At the Horváth Csaba Memorial Laboratory Steve provides technical advice and supports the groups fundamental research and development of new applications in the area of CE and CE-MS.

Patrick Buckley obtained his PhD in protein crystallography from the University of Sheffield in 2001. Pat moved to the Biopharma industry after being a Research Associate in the lab of Martin Humphries at the University of Manchester where he continued his research into protein structure. Previously a Senior Research Scientist at Antibody Applications, Pat has worked at Angel Biotechnology, ICON and AstraZeneca and is a subject matter expert in protein analysis and method development and validation. Pat is currently a senior validation specialist in the Analytical Science & Technology group at Seqirus where he is responsible for the analysis, stability and quality testing of influenza vaccine products.

Webinar:
Influenza vaccine viral protein profiling for viral potency

Webinar Abstract:

In this talk today we will discuss a new approach to profile influenza proteins. Influenza vaccines typically consist of either attenuated, in-activated virus or virosomes which are virus- like particles, which contain antigenic proteins. The viral potency is normally measured by quantitation of a protein hemagglutinin (HA) which is a glycoprotein embedded in the viral bilayer and on the virus outer surface contained in the virosomes.
The solution demonstrated in this webinar uses commercially available kits and prebuilt cartridges together with capillary electrophoresis (CE) to profile the influenza viral proteins. It is based on the separation of viral proteins by capillary gel electrophoresis with sodium dodecyl sulphate (CE-SDS) which is an application which has traditionally been used in quality control of monoclonal antibodies produced by biopharmaceutical companies for over 15 years.

Earn PACE Credits:
1. Make sure you're a registered member of LabRoots (https://www.labroots.com/ms/webinar/influenza-vaccine-viral-protein-profiling-viral-potency)
2. Watch the webinar on the LabRoots Website (https://www.labroots.com/ms/webinar/influenza-vaccine-viral-protein-profiling-viral-potency)
3. Click Here to get your PACE credits (Expiration date – FEB 10, 2023): (https://www.labroots.com/credit/pace-credits/5315)

LabRoots on Social:
Facebook: https://www.facebook.com/LabRootsInc
Twitter: https://twitter.com/LabRoots
LinkedIn: https://www.linkedin.com/company/labroots
Instagram: https://www.instagram.com/labrootsinc
Pinterest: https://www.pinterest.com/labroots/
SnapChat: labroots_inc

Видео Influenza vaccine viral protein profiling for viral potency канала Labroots